• Nuwellis entered a co-promotion and distribution agreement with Atrility Medical for Atrility’s FDA-cleared AtriAmp device.
• Initial six-month pilot covers three Nuwellis sales territories across about nine Western states and five Southeastern states.
• Nuwellis earns commissions on AtriAmp sales to existing and new customers in the covered territories.
• Deal could shift to exclusive U.S. distribution for much of the country if the pilot succeeds.
• Expanded role would have Nuwellis buy AtriAmp from Atrility, then handle sales, distribution, order fulfillment in the covered market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuwellis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250830PRIMZONEFULLFEED9815322) on August 25, 2026, and is solely responsible for the information contained therein.